medannex.org valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Allow: /wp-admin/admin-ajax.php Disallow: /wp-admin/ Sitemap: https://medannex.org/sitemap.xml Sitemap: | ||
Meta Tags
| Title | Home page - |
| Description | unlocking the therapeutic potential of targeting Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. “MDX-124 could provide a new treatment option as a single agent or in combination with |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 160.153.129.39 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
medannex.org Valuation
|
US$798,552
Last updated: 2023-05-12 20:47:31
medannex.org has Semrush global rank of 13,254,383. medannex.org has an estimated worth of US$ 798,552, based on its estimated Ads revenue. medannex.org receives approximately 92,141 unique visitors each day. Its web server is located in United States, with IP address 160.153.129.39. According to SiteAdvisor, medannex.org is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$798,552 |
| Daily Ads Revenue | US$738 |
| Monthly Ads Revenue | US$22,114 |
| Yearly Ads Revenue | US$265,365 |
| Daily Unique Visitors | 6,143 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| medannex.org. | A | 10799 | IP: 160.153.129.39 |
| medannex.org. | NS | 3600 | NS Record: ns77.domaincontrol.com. |
| medannex.org. | NS | 3600 | NS Record: ns78.domaincontrol.com. |
| medannex.org. | MX | 1800 | MX Record: 40 mx4.mtaroutes.com. |
| medannex.org. | MX | 1800 | MX Record: 10 mx1.mtaroutes.com. |
| medannex.org. | MX | 1800 | MX Record: 20 mx2.mtaroutes.com. |
| medannex.org. | MX | 1800 | MX Record: 30 mx3.mtaroutes.com. |
| medannex.org. | TXT | 1800 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
HtmlToTextCheckTime:2023-05-12 20:47:31
| About Innovation Team Ethos Careers News Publications Contact unlocking the therapeutic potential of targeting annexin-A1 Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. “MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies, and clinical trials are now eagerly anticipated.” Professor Daniel Palmer, Department of Molecular & Clinical Cancer Medicine, University of Liverpool Our goal is to improve the lives of people impacted by cancers and autoimmune diseases with our first-in-class therapy targeting annexin-A1. Supported by both Scottish Enterprise and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology. Having completed pivotal toxicology studies and cGMP manufacturing of our lead candidate |
HTTP Headers
HTTP/1.1 301 Moved Permanently Date: Mon, 20 Dec 2021 00:26:08 GMT Server: Apache Location: https://medannex.org/ Content-Type: text/html; charset=iso-8859-1 HTTP/2 200 x-powered-by: PHP/7.4.26 vary: Accept-Encoding,Cookie cache-control: max-age=3, must-revalidate content-length: 28347 last-modified: Mon, 20 Dec 2021 00:23:36 GMT content-type: text/html; charset=UTF-8 date: Mon, 20 Dec 2021 00:26:08 GMT server: Apache |
medannex.org Whois Information
WHOIS LIMIT EXCEEDED - SEE WWW.PIR.ORG/WHOIS FOR DETAILS |